Eledon Pharmaceuticals, Inc.

NasdaqCM:ELDN Stok Raporu

Piyasa değeri: US$253.9m

Eledon Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Eledon Pharmaceuticals şirketinin toplam hissedar öz sermayesi $76.1M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $114.6M ve $38.5M dir.

Anahtar bilgiler

0%

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranın/a
NakitUS$78.19m
EşitlikUS$76.06m
Toplam yükümlülüklerUS$38.52m
Toplam varlıklarUS$114.58m

Son finansal sağlık güncellemeleri

Recent updates

Eledon: Changing Scope Of Immunosuppressive Drug Space With Tegoprubart

Oct 29

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Mar 22
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Dec 05
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

Aug 10
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Apr 27
We Think Eledon Pharmaceuticals (NASDAQ:ELDN) Needs To Drive Business Growth Carefully

Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Jan 05
Here's Why We're Watching Eledon Pharmaceuticals' (NASDAQ:ELDN) Cash Burn Situation

Eledon adds 10% as FDA clears clinical trial for kidney disease candidate

Sep 06

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Aug 31
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Invest In Growth?

Eledon gets FDA nod to start trial of organ rejection preventing therapy

Aug 01

Eledon begins dosing in early-stage study of tegoprubart in kidney transplant patients

Jul 18

Eledon gives update on development strategy for AT-1501 in renal transplantation

Apr 26

Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

Apr 14
Eledon Pharmaceuticals (NASDAQ:ELDN) Is In A Good Position To Deliver On Growth Plans

What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Feb 21
What Type Of Shareholders Make Up Eledon Pharmaceuticals, Inc.'s (NASDAQ:ELDN) Share Registry?

Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Dec 30
Here's Why We're Not Too Worried About Novus Therapeutics' (NASDAQ:NVUS) Cash Burn Situation

Novus Therapeutics (NVUS) Investor Presentation - Slideshow

Dec 18

Novus Therapeutics EPS misses by $3.76

Nov 16

Enrollment underway in Novus Therapeutics' mid-stage AT-1501 trial in neuromuscular disease

Nov 02

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ELDN 'nin kısa vadeli varlıkları ( $81.5M ) kısa vadeli yükümlülüklerini ( $12.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: ELDN şirketinin kısa vadeli varlıkları ( $81.5M ) uzun vadeli yükümlülüklerini ( $26.0M ) aşmaktadır.


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ELDN borçsuzdur.

Borcun Azaltılması: ELDN un 5 yıl önce borcu yoktu.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ELDN şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: ELDN serbest nakit akışı tahminlerine göre 11 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.


Sağlıklı şirketleri keşfedin